Mealey's (February 7, 2018, 11:43 AM EST) -- WASHINGTON, D.C. — In a Feb. 6 decision, the Federal Circuit U.S. Court of Appeals agreed with a Delaware federal judge that two patents relating to the injectable bivalirudin drug Angiomax are not infringed by a series of abbreviated new drug applications (ANDAs) but remanded the case for a determination of whether the on-sale bar set forth at 35 U.S. Code Section 102(b) applies (The Medicines Company v. Hospira Inc., Nos. 2014-1469, -1504, Fed. Cir.)....